Urokinase-plasminogen activator (uPA) inhibitor WX-UK1 in combination with Capecitabine in Advanced Malignancies
This study is currently recruiting patients.
Sponsored by: |
Wilex
|
Information provided by: |
Wilex |
Purpose
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics
of the combination of WX-UK1 and capecitabine in patients with advanced malignancies.
Condition
|
Treatment or Intervention |
Phase |
Advanced malignancies
|
Drug: WX-UK1 in combination with Capecitabine
|
Phase I
|
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Further Study Details:
Expected Total Enrollment:
33
Study start: May 2004
Eligibility
Ages Eligible for Study:
18 Years and above,
Genders Eligible for Study:
Both
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of a non-hematologic malignancy that is either unresponsive to currently
available therapies or for which there is no known effective therapy.
- Patient willing to give informed consent, understand and comply with study procedures/restrictions
- Age>=18
- Patients must have an ECOG performance status of 0, 1, or 2
- Life expectancy of > 12 weeks
- Negative serum pregnancy test for women of child-bearing potential and not nursing. Fertile patients must use effective contraception
during and for 30 days (women) or 4 months (men) after treatment with WX-UK1.
- Measurable or non-measurable disease. Patients without clinical or radiologic evidence of disease are not eligible.
- Laboratory parameters (obtained within the screening period): WBC >= 3 G/L, neutrophils >= 1.5 G/L, platelets >= 100 G/L,
Hgb >= 9 g/dL), total bilirubin <= 1.5 x ULN, ASAT/ALAT/AP/GGT <= 2.5 x ULN, serum creatinine <= 2 x ULN.
Exclusion Criteria:
- History of hypersensitivity to the study drugs or chemically related compounds or any of the excipients
- History of or current neurological disorder, in particular an active or treated seizure disorder
- Known standard therapy for the patient’s disease that is potentially curative or known to extend life expectancy.
- Carcinomatous meningitis or untreated/uncontrolled metastatic brain parenchymal disease.
- Concurrent or prior (within 4 weeks prior to start of WX-UK1 treatment for cytotoxic chemotherapy, biological-, endocrine-,
investigational- or radiotherapy and 6 weeks for nitrosoureas, mitomycin-C)
- Uncontrolled infection
- Significant cardiac disease (NYHA classification III or IV
- Contraindication to an infusion volume of 1000 ml over 2 h
- History of or current blood coagulation disorders
- History of or current bleeding disorder (including cerebral bleeding, recurrent massive nose bleeds, hematuria or unexplained
bruising)
- Diabetes mellitus, if not controlled by insulin, oral anti-diabetic agents or diet alone
- Anticoagulant or thrombolytic therapy within four weeks prior to start of treatment (except heparin flush to keep a port open
or coumadin 1 mg/day or ASA 100mg/d)
- Active serious illness that renders the patient unsuitable for study entry or multiple blood sampling
- Illness or condition that might alter the absorption, distribution, metabolism and elimination of WX-UK1
- Known Hepatitis B/C or HIV infection
- Contraindication to capecitabine intake as specified in the SPC such as DPD-deficiency or concomitant intake of sorivudine
or sorivudine related compounds
- Known hemorrhagic brain metastasis
Location
and Contact
Information
Pennsylvania Fox Chase Cancer Center, Philadelphia,
Pennsylvania,
19111,
United States; Recruiting
Lori Goldstein, Dr.
215-728-2191
Lori Goldstein, Dr., Principal Investigator
More Information
Study ID Numbers:
WX/50-005
Record last reviewed:
May 2004
Record first received:
May 25, 2004
ClinicalTrials.gov Identifier:
NCT00083525Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-09